Eksborg S, Stendahl U, Lönroth U
Eur J Clin Pharmacol. 1986;30(5):629-31. doi: 10.1007/BF00542426.
The plasma pharmacokinetics of adriamycin and 4'epi-adriamycin have been studied in 6 patients with ovarian carcinoma after simultaneous intravenous administration of equal amounts of the two anthracyclines. A highly selective liquid chromatographic analytical method permitted quantification of plasma concentrations of the two drugs as well as their corresponding 13-hydroxy metabolites. The plasma concentrations of each drug followed a three-compartment open model, with great interindividual variation in the pharmacokinetic parameters. On average, the area under the plasma concentration time curve (AUC) and the maximum plasma concentration (Cmax) were 1.6- and 1.2-times larger for adriamycin than for 4'epi-adriamycin. 4'Epi-adriamycin was eliminated faster than adriamycin by 4 of the 6 patients, the average terminal half-life of the latter being 1.4-times longer. The plasma concentrations of the 13-hydroxy metabolites did not exceed 20 ng/ml. Their AUC values averaged 23% of those of the intact drugs.
在6例卵巢癌患者中,同时静脉注射等量的阿霉素和4'-表阿霉素后,对其血浆药代动力学进行了研究。一种高选择性液相色谱分析方法能够对两种药物及其相应的13-羟基代谢产物的血浆浓度进行定量。每种药物的血浆浓度均符合三室开放模型,药代动力学参数存在很大的个体差异。平均而言,阿霉素的血浆浓度-时间曲线下面积(AUC)和最大血浆浓度(Cmax)分别是4'-表阿霉素的1.6倍和1.2倍。6例患者中有4例的4'-表阿霉素比阿霉素消除得更快,后者的平均终末半衰期长1.4倍。13-羟基代谢产物的血浆浓度不超过20 ng/ml。其AUC值平均为完整药物的23%。